Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Optimization of the Expression of Reteplase in Escherichia coli TOP10 Using Arabinose Promoter

Fatemeh Shafiee 1 , Fatemeh Moazen 1 , Mahammad Rabbani 1 and Hamid Mir Mohammad Sadeghi 1 , *
Authors Information
1 Department of Pharmaceutical Biotechnology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: February 01, 2015, 10 (1); e16676
  • Published Online: February 19, 2015
  • Article Type: Research Article
  • Received: December 15, 2013
  • Revised: January 27, 2014
  • Accepted: February 23, 2014
  • DOI: 10.17795/jjnpp-16676

To Cite: Shafiee F, Moazen F, Rabbani M, Mir Mohammad Sadeghi H. Optimization of the Expression of Reteplase in Escherichia coli TOP10 Using Arabinose Promoter, Jundishapur J Nat Pharm Prod. 2015 ; 10(1):e16676. doi: 10.17795/jjnpp-16676.

Copyright © 2015, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML. Acute myocardial infarction. Lancet. 2003; 361(9360): 847-58[DOI][PubMed]
  • 2. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993; 329(10): 673-82[DOI][PubMed]
  • 3. Baruah DB, Dash RN, Chaudhari MR, Kadam SS. Plasminogen activators: a comparison. Vascul Pharmacol. 2006; 44(1): 1-9[DOI][PubMed]
  • 4. Rijken DC. Relationships between structure and function of tissue-type plasminogen activator. Klin Wochenschr. 1988; 66 Suppl 12: 33-9[PubMed]
  • 5. Emeis JJ, van den Hoogen CM, Jense D. Hepatic clearance of tissue-type plasminogen activator in rats. Thromb Haemost. 1985; 54(3): 661-4[PubMed]
  • 6. Hotchkiss A, Refino CJ, Leonard CK, O'Connor JV, Crowley C, McCabe J, et al. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemost. 1988; 60(2): 255-61[PubMed]
  • 7. Kuiper J, Van't Hof A, Otter M, Biessen EA, Rijken DC, van Berkel TJ. Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions. Biochem J. 1996; 313 ( Pt 3): 775-80[PubMed]
  • 8. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature. 1983; 301(5897): 214-21[PubMed]
  • 9. Weaver WD. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials. Eur Heart J. 1996; 17 Suppl F: 9-15[PubMed]
  • 10. Koda-Kimble MA. Rising women. J Am Pharm Assoc (2003). 2012; 52(5): 579-80[DOI][PubMed]
  • 11. Hilleman D, Campbell J. Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review. Pharmacotherapy. 2011; 31(10): 1031-40[DOI][PubMed]
  • 12. Dormiani K, Khazaie Y, Sadeghi HM, Rabbani M, Moazen F. Cloning and expression of a human tissue plasminogen activator variant: K2S in Escherichia coli. Pak J Biol Sci. 2007; 10(6): 946-9[PubMed]
  • 13. Daniels CJ, Bole DG, Quay SC, Oxender DL. Role for membrane potential in the secretion of protein into the periplasm of Escherichia coli. Proc Natl Acad Sci U S A. 1981; 78(9): 5396-400[PubMed]
  • 14. Yu P. Enhancing survival of Escherichia coli by increasing the periplasmic expression of Cu,Zn superoxide dismutase from Saccharomyces cerevisiae. Appl Microbiol Biotechnol. 2007; 76(4): 867-71[DOI][PubMed]
  • 15. Sambrook J, Russell DW, Russell DW. Molecular cloning: a laboratory manual (3-volume set). 2001;
  • 16. Bajorunaite E, Sereikaite J, Bumelis VA. L-arginine suppresses aggregation of recombinant growth hormones in refolding process from E. coli inclusion bodies. Protein J. 2007; 26(8): 547-55[DOI][PubMed]
  • 17. Shen T, Zhang AH, Bi L, Shi LR. [Construction, expression and identification of a single chain antibody variable (scFv) against human CD25 molecule]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007; 23(3): 264-6[PubMed]
  • 18. Gerami SM, Farajnia S, Mahboudi F, Babaei H. Optimizing refolding condition for recombinant tissue plasminogen activator. Iran J Biotechnol. 2011; 9(4): 253-9
  • 19. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med. 1993; 329(22): 1615-22[DOI][PubMed]
  • 20. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation. 1993; 87(6): 1829-39[PubMed]
  • 21. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol. 1993; 21(6): 1391-5[PubMed]
  • 22. Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA. 1993; 270(10): 1211-6[PubMed]
  • 23. Jung S, Park S. Improving the expression yield of Candida antarctica lipase B in Escherichia coli by mutagenesis. Biotechnol Lett. 2008; 30(4): 717-22[DOI][PubMed]
  • 24. Makrides SC. Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol Rev. 1996; 60(3): 512-38[PubMed]
  • 25. Wooster MB, Luzier AB. Reteplase: a new thrombolytic for the treatment of acute myocardial infarction. Ann Pharmacother. 1999; 33(3): 318-24[PubMed]
  • 26. Qiu J, Swartz JR, Georgiou G. Expression of active human tissue-type plasminogen activator in Escherichia coli. Appl Environ Microbiol. 1998; 64(12): 4891-6[PubMed]
  • 27. Majidzadeh AK, Mahboudi F, Hemayatkar M, Davami F, Barkhordary F, Adeli A, et al. Human Tissue Plasminogen Activator Expression in Escherichia coli using Cytoplasmic and Periplasmic Cumulative Power. Avicenna J Med Biotechnol. 2010; 2(3): 131-6[PubMed]
  • 28. Saito Y, Ishii Y, Sasaki H, Hayashi M, Fujimura T, Imai Y, et al. Production and characterization of a novel tissue-type plasminogen activator derivative in Escherichia coli. Biotechnol Prog. 1994; 10(5): 472-9[DOI][PubMed]
  • 29. Lee HJ, Im HN. Soluble Expression and Purification of Human Tissue-type Plasminogen Activator Protease Domain. Bull Korean Chem Soc. 2010; 31(9): 2607-12[DOI]
  • 30. Choi JH, Lee SY. Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol. 2004; 64(5): 625-35[DOI][PubMed]
  • 31. Mergulhao FJ, Summers DK, Monteiro GA. Recombinant protein secretion in Escherichia coli. Biotechnol Adv. 2005; 23(3): 177-202[DOI][PubMed]
  • 32. Jonasson P, Liljeqvist S, Nygren PA, Stahl S. Genetic design for facilitated production and recovery of recombinant proteins in Escherichia coli. Biotechnol Appl Biochem. 2002; 35: 91-105[PubMed]
  • 33. Sorensen HP, Mortensen KK. Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol. 2005; 115(2): 113-28[DOI][PubMed]
  • 34. Baneyx F. Recombinant protein expression in Escherichia coli. Curr Opin Biotechnol. 1999; 10(5): 411-21[PubMed]
  • 35. Khlebnikov A, Datsenko KA, Skaug T, Wanner BL, Keasling JD. Homogeneous expression of the P(BAD) promoter in Escherichia coli by constitutive expression of the low-affinity high-capacity AraE transporter. Microbiology. 2001; 147: 3241-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments